期刊文献+

阿托伐他汀钙治疗老年冠心病合并高脂血症的疗效观察 被引量:30

Clinical effect of atorvastatin calcium in the treatment of elder patients with coronary heart disease complicated with hyperlipidemia
下载PDF
导出
摘要 目的观察阿托伐他汀钙对高脂血症的疗效和安全性。方法将68例高脂血症合并冠心病的老年患者随机均分为观察组和对照组,观察组给予阿托伐他汀钙10mg,对照组给予辛伐他汀10mg,1d1次,疗程均为8周,检测并分析患者治疗前后血脂变化、不良反应发生情况和肝功、肌酸激酶水平。结果治疗8周后,观察组总胆固醇(TC)、低密度脂蛋白(LDL-C)和三酰甘油(TG)明显下降,高密度脂蛋白(HDL-C)轻度升高;观察组与对照组差异有统计学意义(P<0.05)。结论阿托伐他汀能显著降低老年冠心病患者的血脂水平,治疗高脂血症安全有效。 Objective To explore the effect and safety of atorvastatin calcium in the patients with coronary heart disease complicated with hyperlipidemia .Methods 68 patients with coronary heart disease complicated with hyperlipidemia were randomly divided in-to simvastatin control group and atorvastatin calcium intervention group .The intervention group was taken atorvastatin calcium 10 mg · d-1 for 8 weeks ,and the control group was taken simvastatin 10 mg · d-1 at the same time .After 8 weeks treatment ,the lev-els of lipid ,liver function ,creatine kinase and other adverse reactions of the two groups were observed .Result The levels of serum TC ,LDL-C and TG in intervention group were decreased significantly ,and the level of HDL-C was higher(P〈0 .05) .The attacks number of heart failure and angina pectoris increased .Conclusion Atorvastatin calcium can decrease the lipid levels in elderly pa-tients with coronary artery disease ,and it is safe and effective for the hyperlipemia treatment .
出处 《西北药学杂志》 CAS 2013年第6期630-631,共2页 Northwest Pharmaceutical Journal
关键词 阿托伐他汀钙 高脂血症 冠心病 atorvastatin calcium hyperlipidemia coronary heart disease
  • 相关文献

参考文献9

  • 1苏克江.动脉粥样硬化性缺血性卒中的二级预防——可纠正危险因素的药物干预[J].中国脑血管病杂志,2009,6(12):666-672. 被引量:1
  • 2姚玉才,李国华.动脉粥样硬化性疾病的一级预防进展[J].心血管病学进展,2012,33(2):147-149. 被引量:7
  • 3Boentowicz-Wikarek M, Kocelak P, Smertka M, et al. Effectiveness of lipid-lowering therapy with statins for secondary prevention of atherosclerosis-guidelines vs. reality[J]. Pharmaeoi Rep, 2012,64(2) : 377-385.
  • 4《中国成人血脂异常防治指南》制订联合委员会.中国成人血脂异常防治指南[M].北京:人民卫生出版社,2007:16-17.
  • 5刘国仗,胡大一,陶萍,诸骏仁,郭林妮,郭静萱,游凯.心血管药物临床试验评价方法的建议[J].中华心血管病杂志,1998,26(1):5-11. 被引量:1439
  • 6Baigent C, Keech A, Kearney P M et al. Efficacy and J safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J]. Lancet, 2005, 366 (9493) . 1267-1278.
  • 7Lee C W,Kang S J, Ahn J M, et al. Comparison of effects of atorvastatin(20 mg) versus rosuvastatin (10 rag) therapy on mild coronary atherosclerotic plaques (from the ARTMAP trial) rJ. Am J Cardiol,2012,109 (12) : 1700-1704.
  • 8Thongtang N,Diffenderfer M R,Ooi E M,et al. Effects of atorvastatin on human C-reactive protein metabolism FJ. Atherosclerosis,2013,226(2) .466-470.
  • 9Jose M A,Anandkumar S,Narmadha M P,et al. A com- parative effect of atorvastatin with other statins in pa- tients of hyperlipidemia [J. Indian J Pharmacol, 2012, 44(2) :261-263.

二级参考文献14

  • 1Sacks D,Bakal CW,Beatty PT,et al.Position statement on the use of the an-kle-brachiaI index in the evaluation of patients with peripheral vascular disease:a consensus statement developed by the standards division of the society of cardi-ovascular&interventional radiology[J].J Vasc Interv Radiol,2003,14(9 pt2):S389.
  • 2Scheen AJ,Kulbertus H.Interheart:nine risk factors predict nine out of tenmyocardial infarctions[J].Rev Med Liege,2004,59(11):676-679.
  • 3Baigent C,Keech A,Kearney PM,et al.Efficacy and safety of cholesterol-low-ering treatment:prospective meta-analysis of data from 90,056 participants in14 randomised trials of statins[J].Lancet,2005,366(9493):1267-1278.
  • 4Krauss RM.Dietary and genetic effects on low-density lipoprotein heterogeneity[J].Ann Rev Nutr,2001,21:283-295.
  • 5Fogelman AM.When good cholesterol goes bad[J].Nat Med,2004,10(9):902-903.
  • 6Wald DS,Wald NJ,Morris JK,et al.Folic acid,homocysteine,and cardio-vascular disease:judging causality in the face of inconclusive trial evidence[J].BMJ,2006,333(7578):1114-1117.
  • 7Sarwar N,Gao P,Seshasai SR,et al.Diabetes mellitus,fasting blood glucoseconcentration,and risk of vascular disease:a collaborative meta analysis of 102prospective studies[J].Lancet,2010,375:2215-2222.
  • 8Gaede P,Vedel P,Larsen N,et al.Multifactorial intervention and cardiovascu-lar disease in patients with type 2 diabetes[J].N Engl J Med,2003,348:383-393.
  • 9ACCORD Study Group,Ginsberg HN,Elam MB.Effects of combination lipidtherapy in type 2 diabetes mellitus[J].N Engl J Med,2010,362(17):1563-1574.
  • 10Ridker PM,Danielson E,Fonesca FA,et al.Rosuvastatin to prevent vascularevents in men and women with elevated C-reactive protein[J].N Engl J Med,2008,359(21):2195-2207.

共引文献1517

同被引文献202

引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部